source
- Agios halts development of sickle cell drug tebapivat after mid-stage trial failureAgios announced it will stop developing tebapivat for sickle cell disease after a mid-stage trial did not meet expectations. The drug, a next-generation pyruvate kinase activator related to the ap…
- Jupiter Neurosciences signs $100M deal for U.S. rights to PharmAla's MDMA therapy ALA-002Jupiter Neurosciences announced a licensing agreement with Canadian biotech PharmAla Biotech to obtain U.S. rights to an MDMA‑based drug, ALA‑002, aimed at treating neuropsychiatric conditions. Th…